Factors associated with withholding of invasive mechanical ventilation in the early phase of the COVID-19 response and their ethical analyses

Author:

Morioka Shinichiro1,Takashima Kyoko2,Asai Yusuke2,Suzuki Tetsuya2,Nomoto Hidetoshi1,Saito Sho1,Suzuki Kumiko3,Suzuki Setsuko2,Sato Lubna2,Nakamura Keiji4,Nikaido Mio2,Matsunaga Nobuaki2,Hayakawa Kayoko1,Mori Masanori5,Yamamoto Keiichiro1,Ohmagari Norio1

Affiliation:

1. National Center for Global Health and Medicine Hospital

2. National Center for Global Health and Medicine

3. Tohoku University

4. Kyushu University Hospital

5. Seirei Mikatahara General Hospital

Abstract

Abstract Background End-of-life decision making regarding invasive mechanical ventilation (IMV) for patients with severe coronavirus disease (COVID-19) is challenging. We aimed to explore the factors associated with the withholding of IMV in patients with COVID-19. Methods This retrospective study included patients registered in a nationwide COVID-19 Registry Japan. We enrolled patients with COVID-19 admitted between January 1, 2020, and June 30, 2021, and died during hospitalisation. The enrolled patients were divided into two groups: those who received IMV (IMV group) and those who did not (non-IMV group). To identify the factors associated with withholding of IMV among patients with COVID-19 who died during hospitalisation, we conducted a multivariate logistic regression analysis. Results A total of 2401 patients were enrolled. Of these, 588 (24.5%) were in the IMV group and 1813 (75.5%) in the non-IMV group. Withholding IMV was positively associated with older age (95% confidence interval [CI]: 0.82–0.88, p < 0.0001), dementia (95% CI: 0.81–0.91, p < 0.0001), chronic lung disease (95% CI: 0.88–1.00, p = 0.036), and malignancy (95% CI: 0.82–0.94, p < 0.0004) although inversely associated with male sex (95% CI: 1.04–1.15, p = 0.0008), body mass index (95% CI: 1.01–1.02, p < 0.0001), and National Early Warning Score (95% CI: 1.01–1.03, p < 0.0001). Conclusions We explored factors associated with the withholding of IMV and analysed the results to prepare for future emerging infectious disease pandemics by taking a retrospective look at the decision-making process during the COVID-19 disaster and considering multidisciplinary collaboration.

Publisher

Research Square Platform LLC

Reference30 articles.

1. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis;Fu L;J Infect,2020

2. End-of-life care in the time of COVID-19: communication matters more than ever;Ersek M;J Pain Symptom Manag,2021

3. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. https://apps.who.int/iris/handle/10665/331446. Accessed 4 May 2023.

4. Clinical epidemiology of hospitalized patients with coronavirus disease 2019 (COVID-19) in Japan: report of the COVID-19 registry Japan;Matsunaga N;Clin Infect Dis,2021

5. Ethical dilemmas in the era of COVID-19;Chamsi-Pasha H;Avicenna J Med,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3